论文部分内容阅读
目的观察吉西他滨或多西紫杉醇联合顺铂方案(GP方案或TP方案)治疗晚期非小细胞肺癌(NSCLC)的近期疗效和毒副作用。方法 85例晚期初治NSCLC患者随机分成2组,分别接受GP方案(n=43)和TP方案(n=42)进行全身静脉化疗,每例患者至少接受2个周期以上的同一方案治疗,比较2种方案治疗的近期疗效、不良反应。结果 GP方案和TP方案的总有效率分别为48.8%、47.6%,2组间近期疗效比较差异无统计学意义(P>0.05)。GP组和TP组的不良反应主要为骨髓抑制和消化道反应,2组血小板减少发生率分别为60.5%、45.2%(P<0.05)。其他不良反应相似,均在可耐受范围。除血小板减少外,2种方案毒副作用相似。结论 GP方案与TP方案对初治晚期NSCLC均有一定疗效,且疗效相似,可作为晚期初治NSCLC的一线化疗方案。
Objective To observe the short-term curative effect and toxicity of gemcitabine or docetaxel combined with cisplatin (GP or TP) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Eighty-five patients with newly diagnosed NSCLC were randomly divided into two groups, receiving systemic chemotherapy with GP regimen (n = 43) and TP regimen (n = 42), respectively. Each patient received at least two cycles of the same regimen. 2 kinds of programs for the treatment of short-term efficacy, adverse reactions. Results The total effective rates of GP regimen and TP regimen were 48.8% and 47.6% respectively. There was no significant difference in the short term efficacy between the two groups (P> 0.05). Adverse reactions of GP group and TP group were mainly myelosuppression and gastrointestinal reaction. The incidences of thrombocytopenia in two groups were 60.5% and 45.2%, respectively (P <0.05). Other adverse reactions are similar, are tolerable range. In addition to thrombocytopenia, the two programs have similar side effects. Conclusion Both GP regimen and TP regimen have certain curative effect on newly diagnosed advanced non-small cell lung cancer (NSCLC) with similar curative effect, which can be used as a first-line chemotherapy regimen for late-stage initial NSCLC.